Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary

May 1, 2025

NASDAQ US Health Care Biotechnology earnings 47 min

Earnings Call Speaker Segments

Chris Taylor

executive
#1

Thanks, operator. Hello, everyone, and good morning. We appreciate you joining Agios' conference call and webcast, where we'll go over our financial results for the first quarter of 2025 along with recent business highlights. Today's slides can be found in the Investors section at agios.com. Speaking on today's call will be our Chief Executive Officer, Brian Goff; our Chief Medical Officer and Head of Research and Development, Dr. Sarah Gheuens; our Chief Commercial Officer, Tsveta Milanova; and our Chief Financial Officer, Cecilia Jones. Before we begin, please be aware that certain statements made today will contain forward-looking statements. Due to a range of risks, uncertainties and other factors, including those described in our most recent SEC filings and any future filings we make with the SEC, actual events and results may differ materially from what those forward-looking statements express or imply. With that said, I'm happy to hand the call over to Brian.

Brian Goff

executive
#2

Thanks, Chris. Morning, everyone, and thanks for being here. At Agios, our mission is to create and provide transformative medicines that lift up and lengthen the lives of people dealing with rare diseases. Right now, we're lucky to have several late-stage programs approaching key data readouts or possible commercialization, plus a very solid balance sheet. We're staying focused on delivering the goals we set out, which includes the active regulatory reviews for our thalassemia program, where FDA interaction has been steady and ongoing. With roughly $1.4 billion in cash available and a careful strategy for allocating capital, we think we'll achieve financial independence to support the company through fresh approvals and product rollouts while pushing our pipeline forward — something particularly noteworthy given the current market conditions. Our top product, PYRUKYND or mitapivat, is a pyruvate kinase activator with a new way of working that enhances red blood cell metabolism and boosts the energy or ATP available to maintain red blood cell health. We have the thrilling possibility of 2 more commercial launches to back our potential multibillion-dollar opportunity for PYRUKYND. We're getting ready for a possible approval and launch in thalassemia within the U.S. in September this year, and then sickle cell disease in 2026. Past PYRUKYND, our early and mid-stage pipeline is strong and ready for clinical progress, providing a solid base for innovation and growth over the long term. And lastly, underpinning everything is our deeply experienced team and that strong balance sheet I mentioned. We see 2025 as a breakout year for Agios, with focus on 3 main priorities: first, maximizing PYRUKYND franchise potential, including chasing new indications. Second, pushing forward and broadening our key pipeline programs; and third, strategically targeting our capital use to maintain and fuel our growth. We've kicked off the year strongly, making progress toward crucial milestones. Earlier in the year, we shared positive top-line findings from the ACTIVATE-Kids T Phase III trial of mitapivat in pediatric PK deficiency patients who aren't regularly transfused. We also expect some thrilling progress for our mid- and early-stage pipeline efforts. For tebapivat, our novel PK activator, we aim to finish enrollment in the current Phase IIb study in lower-risk MDS by year-end and start enrollment in a Phase II study in sickle cell disease by mid-2025. Plus, we plan to submit an investigational new drug application for AG-236, our siRNA targeting TMPRSS6 inhibition meant to treat polycythemia vera, in mid-2025. The biggest expected events for 2025 involve the September 7 PDUFA goal date for our sNDA filing of PYRUKYND in thalassemia — just 4 months from now — and the Phase III readout of the RISE UP study of mitapivat in sickle cell disease by year-end. As you can tell, this year should be thrilling, with numerous catalysts throughout our pipeline that carry major value for shareholders and could transform things for patients. Ahead of handing things to Sarah, I want to officially welcome Krishnan Viswanadhan. He came aboard in March as our Chief Corporate Development and Strategy Officer. Before this, he was President and Chief Operating Officer at Be Biopharma, and he held several senior positions at Bristol-Myers Squibb as well as Celgene. His wide-ranging background and strategic insight are going to be key as we work to get the most out of the assets we have today and also look into possible chances to expand. So with that, I'll pass it to Sarah now.

Sarah Gheuens

executive
#3

Thanks, Brian. Our pipeline features a balanced combination of late-stage programs that are close to reaching the market, along with encouraging opportunities in the mid- and early stages. Thalassemia is an uncommon, inherited blood condition that persists for life and results in chronic anemia, and those with thalassemia frequently endure numerous debilitating complications, including organ damage, stroke, and other severe health problems. Chronic fatigue ranks among the most frequently mentioned patient concerns, and existing therapies do not address it. Typical approaches to managing thalassemia, including blood transfusions and iron chelation therapy, may additionally cause considerable secondary effects, intensifying the health difficulties these patients encounter. At present, individuals have few or no effective treatment choices, since 67% of diagnosed patients in the U.S. lack approved therapies; during 2024, we reported positive findings from the ENERGIZE and ENERGIZE-T Phase III trials assessing mitapivat against placebo in adults with non-transfusion-dependent and transfusion-dependent alpha or beta-thalassemia, respectively. Given the compelling clinical profile seen in both the ENERGIZE and ENERGIZE-T Phase III studies, we think mitapivat could emerge as a foundational and convenient oral medication for thalassemia patients, irrespective of their genotype or transfusion requirements. In December, we disclosed the simultaneous submission for regulatory approval of PYRUKYND for this indication across the U.S., European Union, Kingdom of Saudi Arabia, and the United Arab Emirates. As Brian noted, here in the U.S., only 4 months remain until our PDUFA goal date of September 7, and our communications with the FDA have proceeded as anticipated. The FDA has indicated that no advisory committee meeting is currently scheduled, and the review continues. Turning to sickle cell disease; this inherited, lifelong blood disorder is believed to impact roughly 120,000 to 135,000 people throughout the U.S; and EU5, while global prevalence surpasses 3 million. Chronic hemolytic anemia and vaso-occlusion are clinical hallmarks of sickle cell disease, potentially resulting in pain, diminished quality of life, organ damage and premature death. A pressing need exists for innovative therapeutic approaches, and the data we have gathered so far suggest mitapivat might serve as a transformational therapy for these patients, capable of addressing multiple facets of the disease. The Phase III RISE UP study finished enrollment in October 2024, with more than 200 patients enrolled worldwide, reaching this milestone only slightly more than a year after recruitment started. Within this study, we have 2 independent primary endpoints, hemoglobin response and analyzed rate of sickle cell pain crises. Achieving either primary endpoint permits us to apply alpha to the testing of the trial's key secondary endpoints. For our secondary endpoints, we are employing a range of measures to evaluate mitapivat's potential in enhancing how patients feel and function; we anticipate reporting top line results from this Phase III study in late 2025, with a possible regulatory filing and U.S. approval in 2026. We think mitapivat could become a best-in-class treatment that tackles the significant unmet need in this disease by bettering anemia, lowering sickle cell pain crises, and helping patients feel better. Past mitapivat, our goal is to tackle the many disease manifestations across various areas of unmet need in sickle cell disease. Because not all patients will respond to a particular therapy, we see a chance to grow the patient population through complementary approaches. For that reason, tebapivat, a potent PK activator now being studied as a possible treatment for low-risk MDS, might also show promise in sickle cell disease. We intend to start enrollment in a Phase II trial of tebapivat in sickle cell disease within the next few months. This will be a randomized, placebo-controlled, dose-finding study involving 56 patients in total. Patients will be assigned randomly to 2.55 or 7.5 milligrams of tebapivat QD or placebo. The primary endpoint will be a hemoglobin response, defined as a rise of at least 1 gram per deciliter from week 10 to 12 relative to baseline, and secondary endpoints will cover hemolysis and patient-reported outcomes assessing how patients feel and function. We anticipate data from this study will offer proof of concept for tebapivat and let us choose the dose for Phase III. As I noted, tebapivat is also under evaluation in a Phase IIb study in lower-risk MDS, where we seek to deliver the first oral therapy that addresses anemia caused by ineffective erythropoiesis in the disease. MDS impacts roughly 75,000 to 80,000 patients in the U.S; and EU5, with lower-risk MDS making up about 70% of all MDS cases; we remain on track to finish enrollment in this study later this year, with a data readout expected in early next year. And last, 2 items to mention in our early-stage pipeline programs. For AG-181 targeting phenylketonuria, we are moving to studying multiple ascending doses in our ongoing healthy volunteer study midyear. We are also on track to file an IND mid-2025 for AG-236, our siRNA targeting TEMPR-6 intended to treat polycythemia vera. So, we are very excited about the progress planned across the whole portfolio this year; with that, I will now hand the call over to Tsveta.

Tsveta Milanova

executive
#4

Thank you, Sarah. What's driving our commercial team is the chance to broaden PYRUKYND's indications so that by 2026 they cover thalassemia along with sickle cell disease. When it comes to thalassemia, our aim is to bring forward the first therapy approved to treat every subtype of the condition; for sickle cell disease, we intend to provide an innovative oral treatment that eases anemia, lowers vaso-occlusive crisis, or VOCs, and alleviates fatigue. Taking these indications together, we see PYRUKYND as representing an opportunity worth billions of dollars. If we look toward the possible U.S. launch in thalassemia, the market forces at work in this disease area underpin a meaningful opportunity for PYRUKYND. Patients with thalassemia have a diagnosis and are recognized within the health care system. How the disease burden manifests is thoroughly described; furthermore, established KOLs and patient advocacy organizations are in place. Every one of these factors should assist in encouraging adoption. Only 4 months remain until a possible U.S. approval, and our team is working hard getting ready for a possible launch. To begin, we are carrying out a strong disease state education effort aimed at patients as well as health care providers. What our campaign emphasizes is thalassemia pathophysiology, its long-term complications and burden, plus why regular monitoring and management matter. In addition, it honors the cultural diversity found among the thalassemia patient community. I'm pleased to share that our team has put together multiple well-attended patient programs in Cantonese, Mandarin and Arabic. Responses from the community have been extremely favorable, and we are arranging further programs as launch preparation continues. Next, we have adjusted our cross-functional team to the right size so that launch succeeds in this bigger, though still rare, market. As an illustration, in PK deficiency our sales force has consisted of 20 professionals. For thalassemia, we have deliberately expanded the sales organization to roughly double that figure. This team is completely committed, concentrating on disease state education and thorough account profiling so that a targeted and efficient launch can happen soon after approval; and third, our market access group is busy reaching out to and informing payers about thalassemia via pre-approval information exchange meetings to make the disease better understood and to help patients get access. What we've heard from payer research and these conversations has been encouraging, with acknowledgment of the unmet need and how strong the product profile is. We anticipate that most patients will be covered under commercial plans. Keep in mind that PYRUKYND's initial coverage in thalassemia will come via the medical exception process while policies continue to take shape. Because of what we've learned and our solid record in PK deficiency, we are positioned well to work through the medical exception process and repeat the success achieved in PK deficiency. Roughly 6,000 adults in the U.S. have a thalassemia diagnosis, and the majority of patients receive that diagnosis before reaching adulthood. Since claims data is available, we can pinpoint where within the health care system these patients receive their care, which gives us useful clarity as we get ready to launch. Among that group, we project that PYRUKYND's initial launch focus will reach about 65% of the adult thalassemia patient population. Our expectation is that individuals whose disease symptoms lead to more regular interactions with the health care system will be the ones prioritized for treatment. This group covers transfusion-dependent patients, and also those who are non-transfusion-dependent yet already dealing with complications or severe fatigue. To find out the leading clinical characteristics that health care providers weigh when writing a prescription for PYRUKYND, we carried out market research. The four attributes ranked as most important were: effect on hemoglobin levels, lessening of transfusion burden, fatigue improvement, and iron overload. With all of these factors in mind, the profile of PYRUKYND is strongly positioned against each of these key criteria. At the heart of our messaging is the transformative profile of PYRUKYND in thalassemia, marked by a number of firsts. It stands as potentially the initial therapy for patients with alpha and beta thalassemia. It is the first oral therapy for this disease, the first treatment showing quality of life improvement among non-transfusion-dependent patients, and the first treatment showing 36-week durability of effect when it comes to lowering transfusion burden. That is what drives us to get PYRUKYND to people who suffer from thalassemia as fast as we can. Last, allow me to give a quick update on revenue for the first quarter. During the first quarter of 2025, net PYRUKYND revenue came to $8.7 million, versus $8.2 million in the first quarter of last year. Within the U.S., 234 patients in total have finished a prescription enrollment form, among them 11 during the first quarter of 2025, which is a 5% rise over the prior quarter. That has resulted in 136 net patients on therapy, which is likewise a 5% gain over the prior quarter, and strong persistence continues to be evident. We believe the capabilities we keep reinforcing through the current launch will supply a foundation, assisting us in maximizing potential U.S. launches in thalassemia in 2025 and in sickle cell disease in 2026. To wrap up, we feel inspired and energized by the possibility of delivering a new therapy to these underserved patient populations across the world. With that, I'll hand the call over to Cecilia.

Cecilia Jones

executive
#5

Thank you, Tsveta. You can find our financial results for the first quarter of 2025 in the press release that went out this morning, and our 10-Q, which we'll file later today, will contain additional detail. Let me take a moment now to give some context and call out a few key points. Net PYRUKYND revenue for the first quarter of 2025 came in at $8.7 million, which is a 6% increase from the $8.2 million recorded in the first quarter of 2024. Revenues fell 19% versus the fourth quarter of 2024, largely because of the year-end stocking benefit and the adjustments to certain revenue reserves that we flagged previously for Q4. During Q1, after the label update in January, we observed increases in both new prescriptions and new patient starts, as Tsveta walked through—and we see that as compelling confirmation of what this product can do. On an annual basis, gross to net has typically landed somewhere between 10% and 20%, and we anticipate it staying in that same band, which lines up with other rare disease launches; quarter-to-quarter, though, there will be some fluctuation. One thing to keep in mind: because we're concentrating on thalassemia disease state education ahead of our September 7 PDUFA date, our expectation for PK deficiency revenue in 2025 is still that it will be roughly level with 2024. Regarding thalassemia, keep in mind that a fair amount of time—several weeks, especially during the launch phase—can elapse from the moment a prescription enrollment form is submitted until the patient actually begins treatment. When you add in the time typically required to establish payer access, what we're really dealing with is closer to a partial quarter in Q4, and that ought to be taken into account when building out revenue projections for 2025. Naturally, we're excited for the September 7 PDUFA date to get here, and the team has prepared thoroughly for it. As we think about 2026 and the years after, we have confidence in the team's capacity to convert the positive market dynamics Tsveta mentioned earlier into a meaningful revenue trajectory for thalassemia. Now, turning back to the first quarter results: cost of sales came in at $1.1 million for the quarter. For Q1, R&D costs came to $72.7 million, which is $4.1 million more than what we saw in the same period of 2024. The main drivers here were higher spending on our workforce along with expenses tied to tebapivat clinical trials in lower-risk MDS and sickle cell disease, though that was partly offset by reduced spending on mitapivat trials in thalassemia and pediatric PKD. SG&A came in at $41.5 million for the first quarter, up $10.5 million versus last year's comparable quarter; the primary reason was greater commercial-related activity, including added head count, as we get ready for a possible approval of PYRUKYND in thalassemia later this year. We're keeping a close eye on whether new tariffs could drive up what we spend on operations, though right now we don't expect any significant effect. For more details on that topic, take a look at the 10-Q we'll be filing later today. Cash, cash equivalents and marketable securities totaled roughly $1.4 billion when the first quarter came to a close. As Brian mentioned, that amount should pair with the product revenue and interest income we're expecting, which would give us the financial independence to go after possible PYRUKYND launches in thalassemia and sickle cell disease, move our existing programs ahead, and grab opportunities to broaden the pipeline through assets discovered both within and beyond the company. To wrap up, our attention stays on building shareholder value, which includes actively controlling our cost base and taking a disciplined approach to allocating cash as we get ready to back possible upcoming PYRUKYND launches. With more milestones this year that could create value ahead, we trust our balance sheet will keep letting us act from a position of strength. I'll hand the call back to Brian now.

Brian Goff

executive
#6

Thanks, Cecilia. For Agios, we think what's left of 2025 is going to be really thrilling, driven by the possible approval and launch of PYRUKYND in thalassemia, a key Phase III data readout in sickle cell disease, plus significant expected momentum throughout our mid- and early-stage pipeline. To wrap up, let me quickly underscore how lucky we are to sit on a very robust balance sheet, giving us the capacity to push forward on our main priorities on our own. As we all contend with today's market conditions, we stay dedicated to prudent cash deployment and building shareholder value over the long term. So with that, I'd like to turn the call over to questions now. Operator, please open the line.

Gregory Renza

analyst
#7

Nice work on the momentum. Brian, it's genuinely useful to hear you verify there won't be an advisory committee for the September PDUFA. I'm just wondering if you could speak to a couple of things: first, has that mid-cycle review taken place yet? My understanding is it should be done by now. I just wanted some clarity on that point. And second, what comes next? Like you said, the interaction with FDA has been solid when you consider labeling and what happens later in the cycle.

Brian Goff

executive
#8

Yeah, absolutely. And like you pointed out, we're very happy with the way things are moving forward. Our dealings with the FDA have stayed quite steady, and the fact that we could state at this point that it's been communicated — no Ad Comm — though naturally, this remains a regulatory review that's still underway. Sarah, would you like to share some perspective on that?

Sarah Gheuens

executive
#9

No, that's precisely your point. We feel good about how things are going. Since we've submitted filings across several areas, we're working with the agencies, correct, and all of it keeps moving forward. We genuinely can't wait for our PDUFA date, September 7.

Brian Goff

executive
#10

And Greg, let me jump in here and really drive home something — I think you could hear how excited Tsveta sounded. We're 4 months out from the PDUFA now. And honestly, the commercial team has done a lot of preparation, and we truly can't wait to reach that date and, with any luck, get the chance to support the patients who depend on us.

Gregory Renza

analyst
#11

And perhaps one more thing, quickly. Speaking in broad terms about the sickle cell patient population, and when you consider tebapivat in particular along with enrollment for it, what effect has the Oxbryta withdrawal and today's market situation had? In your estimation, how has that shaped trial recruitment and the sickle cell community as they go through this transition and wait for fresh choices to arrive on the market?

Brian Goff

executive
#12

Sure. Absolutely. Sarah can begin, and then Tsveta may wish to offer a bit more context regarding sickle cell overall and the chance sitting right in front of us.

Sarah Gheuens

executive
#13

Yeah. So obviously, from where we sit, we felt let down when Oxbryta got pulled, since our whole aim is to find every drug that might help patients, and we hope that eventually people living with sickle cell disease will have plenty of choices available. As far as how our trials are being run, we haven't seen anything shift when it comes to our programs.

Tsveta Milanova

executive
#14

Yes. And to build on what Sarah said, commercially speaking, sickle cell disease represents a big market for us, naturally. In the U.S., there are more than 100,000 patients. When Oxbryta was withdrawn, it was devastating for the community, and that only reinforces the unmet medical need; we're excited about the potential opportunity to have 2 products on the market to serve that community and for us to keep growing the number of patients who can benefit from an innovative therapy. When it comes to kind of the sentiment, of course, we're going to take that into account as our launch preparations and the engagement with the community; they deserve the trust and respect and we'll continue to do so.

Alec Stranahan

analyst
#15

Congratulations on the advances made during this quarter. Perhaps to begin, given that you mentioned it on a few occasions, could you remind everyone of your strategy for bringing mitapivat to markets outside the U.S.? At what point might those approvals be granted? Also, considering the strength of your balance sheet, does it seem wise to retain the economics internally by handling those launches on your own? Then I have one more question.

Brian Goff

executive
#16

Sure. Appreciate it, Alec. I'll hand that question over to Tsveta. To begin, let me simply emphasize that the 2 most critical geographies for thalassemia are, by a wide margin, first the U.S; and second the Gulf region, GCC, and for both of those we are extremely well-prepared.

Tsveta Milanova

executive
#17

Certainly. Regarding markets outside the U.S., as Sarah mentioned, we've filed with four regulatory agencies — the UAE, Saudi Arabia, and Europe — with commercial launch readiness and priority in mind. For us, the next market we're focused on is Saudi Arabia, or the GCC area. Looking at the opportunity beyond the U.S., and considering launch, timing, and uptake, I'd say the Gulf nations in particular resemble the European market much more closely. That means there's a gap between approval and actually securing formulary placement, reaching patients, and observing uptake. In the Gulf, we have a very solid partner in NewBridge, and we're confident they're well-positioned to pair our deep thalassemia know-how with their extensive regional knowledge to carry out the launch on our behalf effectively.

Brian Goff

executive
#18

And on economics, maybe Cecilia, you can touch on that.

Cecilia Jones

executive
#19

Absolutely, Alec — regarding the economics: as we shared last year, there's a partnership in place with NewBridge. What I'd describe as a revenue split, it lets us take advantage of, in a way, the strongest aspects of each side — as Sarah mentioned, NewBridge's familiarity with the region combined with our team support's understanding of the product — and for us it's an efficient method of deploying capital. In Europe, we intend to pursue a quite comparable approach when it comes to the structure, and once that's done, we'll give you an update.

Alec Stranahan

analyst
#20

And so perhaps, first off, it's wonderful to see Krishnan become part of the team. I'm wondering whether adding him to spearhead corporate strategy signals any changes in how you're approaching things or distributing resources moving forward, whether via more business development or particular areas of pipeline emphasis?

Brian Goff

executive
#21

Yeah, thank you. Having Krishnan here makes me genuinely pleased. As I mentioned in my remarks earlier, he's an extremely seasoned leader who has worked at numerous companies in senior positions, and he's an individual with excellent connections, so we're simply thrilled that he's with us. Regarding what you asked, this isn't a change. What it actually amounts to is capability-building and a strengthening of where our true emphasis lies for corporate strategy, and in particular capital allocation. Priority-wise, number one is executing properly on these launches; as we've said, we're truly enthusiastic about thalassemia at this point, with the PDUFA only 4 months off. We feel just as enthusiastic regarding the RISE UP data that's going to unfold by the close of this year, and that might set up a back-to-back launch situation, with a sickle cell launch coming near the end of 2026; beyond that, we aren't a company built around a single product. We take real pride in discussing the mid and early sections of our pipeline right now. So that's a major priority. Then third comes BD. Every robust biopharma and biotech firm ought to consistently examine ways to keep expanding the pipeline; and our balance sheet is quite strong. As I said, we'll be incredibly disciplined, since we have in-house opportunities that establish a very demanding standard. Still, Krishnan genuinely enhances that capability. And once more, we're simply thrilled that he's with us.

Divya Rao

analyst
#22

This is Divya, filling in for Mark. I'd like to add my congratulations regarding all the headway. We just have one question. With the recent reorganization going on at the agency, have you noticed any difference in how often you communicate with the FDA? Also, when it comes to a potential Ad Comm, is there a cutoff date by which the FDA has to let you know?

Sarah Gheuens

executive
#23

Thanks for that question, Divya. No, our interactions with the agency regarding our programs remain unchanged. I'd characterize it as the usual exchange in the setting of — particularly for the filing, it's the typical dialogue of questions and answers; so, as you're aware, September 7 is the PDUFA date, and since the review is still underway, the agency can always ask for an advisory committee. Up to now, however, they've told us that no advisory committee is scheduled and that the review continues.

Brian Goff

executive
#24

Divya, I want to use this moment to acknowledge the FDA, since we're all aware there's been plenty of activity in this space. That said, I believe it underscores something important: this is an area of significant unmet need, and we have 2 outstanding studies that reported out last year. The data included in our filing lines up remarkably well with what we keep hearing about the unmet need we're working to address. So we're grateful for that ongoing attention, and genuinely happy with the pace of our progress.

Hiro Nagayumi

analyst
#25

Hiro from Cantor, speaking for Eric Schmidt — I'd like to understand the thinking and confidence behind launching the Phase II tebapivat trial in sickle cell during mid-2025, ahead of the Phase III data for PYRUKYND coming in late 2025.

Brian Goff

executive
#26

Right. Hiro, once more, this will come in 2 parts, I believe. Sarah ought to begin by covering tebapivat as such and the reasons we feel enthusiastic about it. After that, Tsveta can say more regarding our goals in sickle cell for patients broadly, which plainly calls for additional options going forward, not a smaller number.

Sarah Gheuens

executive
#27

Hiro, we were really happy with the Phase I results we've produced for tebapivat in sickle cell disease. And if you consider drug development for that particular program, it lets us advance into a Phase II, and we're quite eager to begin that around mid-year. Then naturally, in drug development, that's the point where Tsveta's group and the R&D group collaborate very closely, since we'll always build our trials around the product profile we think is capable of delivering meaningful change. With that said, I'll pass things to Tsveta.

Tsveta Milanova

executive
#28

Sure, here's how I think about it, basically in three parts. First, there are 100,000 patients, and the unmet medical need is very large. Looking at a market like this, it can easily take in multiple therapies, and that need supports them. Second, we keep hearing this loud and clear from KOLs, physicians, and experts in the field. Not every patient is going to respond to any single therapy, so they want many options available to choose from and to find what works best for their treatment. As for timing and how the 2 products are co-positioned, our aim is really to grow the patient population through our portfolio of products. More specifically, as Sarah said, we'll position tebapivat once we have the mitapivat data, the RISE UP data; so starting now lets us actually have both data sets and make the best informed decisions for ourselves on how to proceed with Phase III.

Brian Goff

executive
#29

I believe those of you on the call might also be familiar with Tsveta's history, yet previously, she gained extensive experience creating enduring franchises that share a quite comparable pattern of catering to an even larger group of patients. Therefore, we intend to make use of her knowledge in that area.

Emily Bodnar

analyst
#30

So regarding thalassemia, could you perhaps say a little about what you intend to do on the marketing side for patients who are not transfusion-dependent versus those who are transfusion-dependent, especially for the non-transfusion group, given that no treatments exist for them right now?

Brian Goff

executive
#31

Yes. Great. Tsveta.

Tsveta Milanova

executive
#32

To begin, I want to express how thrilled we are about the possible thalassemia launch, which is only 4 months off. Our team is in place, and I'm able to say we're prepared to launch — that's genuinely thrilling and motivating. Regarding the market, let me note briefly that it's a highly appealing rare disease space. Patients have been diagnosed and are recognized by the health care system. There's solid knowledge and a clear picture of the unmet need among both transfusion-dependent and non-transfusion-dependent patients. Our disease state education mainly targets the non-transfusion-dependent group, which ties directly to what you asked. And naturally, established KOLs along with patient advocacy groups exist to assist us in driving adoption. As for how we prioritize and take different approaches with each patient population, we think PYRUKYND offers a compelling value proposition for both transfusion-dependent and non-transfusion-dependent patients. At launch, our initial focus will be applied equally toward transfusion-dependent patients as well as non-transfusion-dependent patients whose hemoglobin levels are below 10, who've already developed complications, or who deal with debilitating fatigue. The rationale is that these individuals are already actively engaged and communicating with their health care providers. They're probably going to learn about the therapy first, and we view them as a solid entry point for our commercial uptake.

Andrew Berens

analyst
#33

Amanda here, filling in for Andy. You folks seem to be bringing up tebapivat more and more often in the context of sickle cell disease, and there's a Phase II that's scheduled to kick off. Can you shed any light on the sorts of distinctions you're drawing in terms of how you picture patients entering that trial and the tebapivat study relative to RISE UP, or any endpoints, any differences there that could be a key focus? What learnings are you carrying over into this new trial? Also, has tebapivat displayed any indication of affecting the liver in these early studies? Or what's your thinking on that?

Brian Goff

executive
#34

Absolutely, Amanda. I'll kick things off with a remark that we'll pursue a highly staged approach to steer how we keep on differentiating, though maybe Sarah could chime in briefly regarding the design itself for the Phase II and then thoughts going forward.

Sarah Gheuens

executive
#35

Thus, the Phase II trial for tebapivat is kind of a typical dose-finding investigation, where we seek proof of concept for tebapivat by examining hemoglobin response; so, in sickle cell disease, I would say this is a very standard form of development. As Tsveta and I talked about before, I believe the real point here is — we're at a stage where the drug demonstrated promise in a Phase I. So now we're advancing it into a Phase II so it can keep building its benefit risk profile. And up to now, no liver signal has been seen with tebapivat; however, we'll keep gathering safety data within that program. And then, as Tsveta pointed out earlier, we collaborate very closely with our commercial team between every development phase to ensure the trials we design can satisfy the product profile that commercial wants met when the trial ends. And how the market changes, how the population expands, and the unmet need among that patient population will determine that. So discussing that is a bit too early at this point, since, clearly, Phase III follows Phase II.

Brian Goff

executive
#36

Once more, this aligns with how we handle capital allocation in a disciplined manner. We're not looking to get ahead of ourselves. In the same way that last year we held off on building our commercial team until the ENERGIZE data readout came in, we're taking a very similar approach as we look to build a sickle cell franchise — we'll gain more insight from the Phase II, and at that point we'll make the right decisions.

Tessa Romero

analyst
#37

Going back to something asked earlier, are you able to say whether or not the mid-cycle meeting has wrapped up? If it has, could you share anything about the big-picture talks regarding labeling? Also, is there any situation in which REMS would be required? Or is it possible to eliminate that possibility right now?

Sarah Gheuens

executive
#38

Tess, thanks for asking. Regarding how things stand with the FDA, they'll let you know when the review ends, and that date is the PDUFA goal date, September 7; so that's the target we're actively pushing toward together with them. During that stretch there are various points of contact, and those might be meetings or questions, or they might not be. Compared with something like the EMA, where at a particular moment you can hand in your filing and afterward get questions on a very specific date, this process is less clearly laid out. As we've said previously, our interaction with the FDA is a collaborative one. Questions are going back and forth between us. That falls within the usual process, and from our standpoint it's a very ordinary level of engagement with the agency at this stage. Like I said, the one thing I'd truly focus on right now is that September 7 date. As for labeling talks, like we've said, the review is still underway, correct? Up to now, nobody has told us an advisory committee will happen, though the review continues, as we've said. Negotiations over labeling generally happen at a later stage within a review cycle; so it's too soon for that. As for whether REMS will be needed, I believe you can only be completely sure once your PDUFA goal date arrives, regarding what the final label says and what will be mandated; but I'd say at this moment we're quite happy with where things stand. From where we sit, it's simply a standard process.

Lydia Erdman

analyst
#39

This is Lydia calling in for Salveen. Congratulations on everything you've accomplished. Perhaps one more item regarding the possible thalassemia approval. Could you share your thoughts on how PYRUKYND's pricing might evolve, considering what payers have told you, the current PKD price, and the size of the patient group here?

Tsveta Milanova

executive
#40

Thanks for asking. I'm eager for September 7, the PDUFA date, so we can discuss pricing with a bit more detail at that point. Naturally, whatever pricing we choose will be tied to what the product offers in terms of value and the label we ultimately receive. Given what we've said so far, thalassemia counts as a rare condition. And as far as payers go, we anticipate that category won't be subject to management. Every conversation and piece of payer research we've conducted suggests strong recognition of the unmet need and quite favorable reactions to the product profile; our market access group is really strong, and I have great confidence in our ability to handle the pricing opportunity in thalassemia successfully.

Brian Goff

executive
#41

Okay, thank you so much, Victor, and I appreciate all of you joining us on today's call. As we've mentioned, we're 4 months into what has been another active year, and we're 4 months out from the PDUFA date for thalassemia, which is truly thrilling; so, at Agios, we genuinely feel we're positioned to bring transformative new therapies to patients and generate substantial long-term value for our shareholders. So, once more, thank you, and we can't wait to talk with each of you again very soon.

Operator

operator
#42

I appreciate everyone for joining in on the call today. That brings the session to an end. You're free to hang up at this point. Have a wonderful day, all of you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.